The CO-RMs consist of carbonyls** of metals such as ruthenium, iron and manganese which are routinely used in clinical treatments. They can be designed to release CO over a period of between 30 minutes and several hours, depending on what is required to treat a particular medical condition.
As well as boosting survival rates and cutting recovery times, the new molecules could ease pressure on hospital budgets by reducing the time that patients need to spend in hospital, for example after an operation. They could even help some patients to avoid going into hospital in the first place.
Professor Mann added: This project provides an excellent example of how non-biological sciences like chemistry can underpin important advances in healthcare.
hemoCORM Ltd, a spinout company set up in 2004 by the University of Sheffield and NPIMR, is now taking the research towards commercialisation. It is hoped that, after further development work, Phase 1 clinical trials can begin in around two years, with deployment in the healthcare sector potentially achievable in around five years.
'/>"/>
| Contact: Natasha Richardson natasha.richardson@epsrc.ac.uk 44-017-934-44404 Engineering and Physical Sciences Research Council Source:Eurekalert |